African Cardiomyopathy and Myocarditis Registry Program (IMHOTEP)
IMHOTEP is designed to clarify the epidemiology, clinical features, genetics, environmental factors, outcome and management of all forms of cardiomyopathy and myocarditis in people from all regions of Africa. Beginning in 2016, the program has been recruiting patients aged at least 13 years with a diagnosis of cardiomyopathy or myocarditis who underwent diagnostic evaluation at participating centres in South Africa and Mozambique. As of 2024, the program has recruited over 600 patients. Participants are followed up annually. Plans are in place to expand recruitment to Botswana, Zimbabwe, Tanzania, Kenya, Uganda, Sudan, Nigeria, Guinea, Sierra Leone and Egypt.
Study design
Registry, Cohort - clinical, Cohort
Number of participants at first data collection
665 (patients)
Recruitment is ongoing
Age at first data collection
≥ 13 years (patients)
Participant year of birth
Varied (patients)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2016
Primary Institutions
University of Cape Town (iYunivesithi yaseKapa, Universiteit van Kaapstad, UCT)
University of the Free State, Bloemfontein (Universiteit van die Vrystaat, Yunivesithi ya Freistata)
University of the Witwatersrand, Johannesburg
Profile paper DOI
Funders
GlaxoSmithKline (GSK)
Medical Research Council (MRC)
Newton Fund
South African Medical Research Council (SAMRC)
Ongoing?
Yes
Data types collected
- Interview – phone
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Secondary data
- None
- None
- Healthcare data
- Mortality data
Engagement
Keywords
